Horizon scanning: Development of tabalumab for rheumatoid arthritis halted

Source: Reuters Health Area: News Eli Lilly and Co have halted development of the experimental anti-B-cell activating (BAFF) human monoclonal antibody tabalumab for rheumatoid arthritis following data from a late-stage trial which showed the drug was unlikely to prove effective.   Tabalumab will continue to be tested in late-stage development as a treatment for systemic lupus erythematosus, and in mid-stage development for multiple myeloma.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news